Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,407 across all filing types
Latest filing 2025-05-01 Director's Dealing
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a formal notification of a share purchase by a Non-Executive Director (Karen Knudsen) of AstraZeneca PLC. It explicitly mentions 'Transaction by Person Discharging Managerial Responsibilities' (PDMR) and provides the required regulatory disclosure details under the EU Market Abuse Regulation. This falls directly under the 'Director's Dealing' category.
2025-05-01 English
Total Voting Rights
Regulatory Filings Classification · 98% confidence The document is a regulatory announcement from AstraZeneca PLC regarding the total number of voting rights and issued share capital, filed in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. This type of disclosure is a standard regulatory requirement for listed companies to inform shareholders of the denominator for interest notification calculations. Since it does not fit into specific categories like 'Share Issue' (which would imply a change event) or 'Major Shareholding' (which is a notification from a shareholder), it falls under the general regulatory filing category.
2025-05-01 English
FIXED-DURATION CALQUENCE RECOMMENDED IN EU FOR CLL
Regulatory Filings
2025-04-29 English
UPDATE ON CAPITELLO-280 PHASE III TRIAL
Regulatory Filings
2025-04-29 English
1ST QUARTER RESULTS
Regulatory Filings
2025-04-29 English
Fixed-duration Calquence recommended in EU for CLL
Earnings Release Classification · 99% confidence The document begins with 'RNS Number : 4900G' and is distributed via 'RNS, the news service of the London Stock Exchange.' This strongly indicates a regulatory news service announcement. The content details a positive opinion from the CHMP (Committee for Medicinal Products for Human Use) regarding AstraZeneca's drug Calquence, based on Phase III trial results. This is a significant corporate event announcement related to regulatory/drug approval status. Since it is a general regulatory announcement distributed via RNS and does not fit neatly into specific categories like Earnings Release (ER), Interim Report (IR), or a specific legal/capital event, the most appropriate classification is the general regulatory filing/announcement category, RNS. Q4 2024
2025-04-29 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.